The drug adalimumab, also known as Humira, is a monoclonal antibody drug that is primarily used to treat arthritis. Since monoclonal antibodies are produced by a single B cell clone, they are much more consistent and useful for the treatment of diseases. These are more effective than polyclonal antibodies because they only bind to one epitope which allows for the standardization of experiments. Humira is used to relieve pain from autoimmune diseases by binding to TFNa. Tumor necrosis factor alpha is believed to be involved in the inflammatory response. When Humira binds to this protein, it decreases the pain that a person experiences with an autoimmune disease.

Humira’s side effects include:
- Serious infections
- Hepatitis B infection in carriers of the virus
- Allergic reactions
- Nervous system problems
- Blood problems
- Heart failure
- Immune reactions including a lupus-like syndrome
- Liver problems
- Psoriasis
These problems primarily occur because of the way that Humira is designed to eliminate some of the pain and inflammation from autoimmune disorders. Since this medication targets TNF blockers, the immune response is suppressed. This can cause asymptomatic infections/ carriers to begin showing signs and symptoms of disease. It can also cause blood problems because the blood cells are not active to help fight infection or clot the blood in the case of an injury. Humira can also make you susceptible to other diseases and infections.

The primary diseases that may arise are tuberculosis and infections caused by viruses, fungi or bacteria that have spread throughout the body. This drug makes you more susceptible because, as described above, TNF blockers suppress the immune system. Therefore, a person with a latent TB infection could progress into active TB. Furthermore, someone who is asymptomatic for a virus, fungus, or bacteria could show signs and symptoms after taking Humira. This drug does impact the innate immune response by decreasing the cytokines that mediate the inflammatory response.















